Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 15 · below the Ichimoku cloud · RSI 28 (oversold) · MACD below its signal · at its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $3.0M | 0.00% | 333.90K | −9.1% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a KYTX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 26, 2026 | Clark Ian ThorntonDirector | Stock Award(Grant) at price 0.00 per share. | 5.1K | — |
| May 26, 2026 | Cohen Frederick E. M.D. Ph.D.Director | Stock Award(Grant) at price 0.00 per share. | 5.1K | — |
| May 26, 2026 | Seidenberg Beth CDirector | Stock Award(Grant) at price 0.00 per share. | 5.1K | — |
| May 26, 2026 | Aktar MertDirector | Stock Award(Grant) at price 0.00 per share. | 5.1K | — |
| Mar 12, 2026 | Grasso MarcChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 10K | — |
| Mar 12, 2026 | Biddle Warner WestonChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 58K | — |
| Mar 12, 2026 | Gehchan Naji M.D.Officer | Stock Award(Grant) at price 0.00 per share. | 18K | — |
| Feb 23, 2026 | Miller Andrew CraigDirector | Stock Award(Grant) at price 0.00 per share. | 11K | — |
| Feb 23, 2026 | Emany Sravan KumarDirector | Stock Award(Grant) at price 0.00 per share. | 11K | — |
| Jan 11, 2026 | Shaw Christi LOfficer and Director | Stock Award(Grant) at price 0.00 per share. | 54.3K | — |
| Dec 17, 2025 | Seidenberg Beth CDirector | Purchase at price 7.50 per share. | 133.3K | $1000.00K |
| Dec 17, 2025 | Westlake Biopartners Fund I, L.P.Beneficial Owner of more than 10% of a Class of Security | Purchase at price 7.50 per share. | 133.3K | $1000.00K |
| Dec 14, 2025 | Walker Karen MarieChief Technology Officer | Conversion of Exercise of derivative security at price 4.83 per share. | 24K | $115.91K |
| Dec 14, 2025 | Walker Karen MarieChief Technology Officer | Sale at price 12.20 per share. | 24K | $292.78K |
| May 28, 2025 | Spiegelman Daniel KeithDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| May 28, 2025 | Clark Ian ThorntonDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| May 28, 2025 | Cohen Frederick E. M.D. Ph.D.Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| May 28, 2025 | Shaw Christi LDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| May 28, 2025 | Seidenberg Beth CDirector and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| May 28, 2025 | Aktar MertDirector | Stock Award(Grant) at price 0.00 per share. | 16.6K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.8 | 2.5 | 5.1 | 2.0 | -3.2 | 4.6 | -18.1 | 16.1 | -19.8 | -15.1 | −38.6% | ||
| 2025 | -13.4 | -12.3 | -32.0 | 19.7 | 10.4 | 20.4 | 16.3 | 3.9 | 61.7 | 16.2 | 10.0 | 22.6 | +151.3% |
| 2024 | -8.6 | -39.0 | -17.2 | -40.1 | 15.5 | -7.3 | -39.1 | -2.2 | 20.7 | -35.2 | −86.2% |
Kyverna Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing cell therapies for patients with autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of stiff person syndrome, myasthenia gravis, and autoimmune diseases. The company is also developing KYV-102, an autologous CD19 CAR T-cell product candidate with whole blood rapid manufacturing; and KYV-201, an allogeneic CD19 CAR T-cell product candidate. It has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
Buy / hold / sell counts